Rxsight INC

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$17Mgeneral payments (2019-2025)

$1.1Mresearch payments (2019-2025)

10,064clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $71K

2020 $176K

2021 $185K

2022 $1.7M

2023 $1.9M

2024 $11M

2025 $1.9M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Ophthalmology $14M

Ophthalmic Plastic and Reconstructive Surgery $1,000K

Optometrist $958K

Cornea and External Diseases Specialist $519K

Glaucoma Specialist $59K

Corneal and Contact Management $47K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

Clinician	Location	Specialty	General payments (2019-2025)
Daniel Schwartz	San Francisco, CA	Ophthalmology	$7,980,162.79
Tamara Fountain	Deerfield, IL	Ophthalmic Plastic and Reconstructive Surgery	$993,629.48
Daniel Durrie	Overland Park, KS	Ophthalmology	$934,709.40
Vance Thompson	Sioux Falls, SD	Ophthalmology	$521,494.43
Brian Shafer	Plymouth Meeting, PA	Cornea and External Diseases Specialist	$419,821.49
Stephen Slade	Houston, TX	Ophthalmology	$381,287.10
Kiper Nelson	Hattiesburg, MS	Ophthalmology	$224,205.18
John Vukich	Wauwatosa, WI	Ophthalmology	$216,289.59
Nicholas Bruns	Flint, MI	Optometrist	$173,724.65
Thomas Newsom	Tampa, FL	Ophthalmology	$161,283.89

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.